Clinical Trials Logo
  1. Home
  2. Plasmodium Vivax
  3. NCT04411836

Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine — EFFORT  

Malaria, Vivax Clinical Trial

Official title:
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine - a Randomized Controlled Trial in P. Vivax Patients

Clinical Trial Summary

Health care facility based, randomized, controlled, open label, superiority trial with 3 arms

Clinical Trial Description

- To assess the effectiveness of a short-course of high dose primaquine (total dose 7mg/kg given unsupervised over 7 days) compared to the current standard low dose primaquine regimen (total dose 3.5mg/kg given unsupervised over 14 days). - To assess the effectiveness of tafenoquine (single dose of 300mg) compared to the short-course high dose primaquine regimen. - To assess the safety of tafenoquine compared to the high and low dose primaquine regimens. - To assess the cost-effectiveness and feasibility of high dose primaquine and tafenoquine compared to the current low dose primaquine regimen ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04411836
Study type Interventional
Source Menzies School of Health Research
Contact Kamala Thriemer, MD, MPH, PhD
Phone 0889468644
Email kamala.ley-thriemer@menzies.edu.au
Status Recruiting
Phase Phase 3
Start date April 25, 2021
Completion date September 30, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05096702 - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting NCT05540470 - Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield N/A
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT03307369 - A Retrospective Study of Severe Plasmodium Vivax
Completed NCT01213966 - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Phase 2
Completed NCT00811096 - Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Phase 2
Terminated NCT03337152 - Assessing a Risk Model for G6PD Deficiency Phase 4
Completed NCT05753150 - Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Completed NCT02751294 - A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT03377296 - Study of Controlled Human Plasmodium Vivax Infection N/A
Completed NCT00486694 - Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria Phase 2
Recruiting NCT05788094 - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Phase 4
Terminated NCT02110784 - Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Phase 2
Not yet recruiting NCT05690841 - FocaL Mass Drug Administration for Vivax Malaria Elimination Phase 3
Not yet recruiting NCT04739917 - Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers Phase 2
Completed NCT03208907 - DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil Phase 3
Completed NCT02184637 - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate Phase 1
Completed NCT01928914 - Tafenoquine Thorough QTc Study in Healthy Subjects Phase 1
Completed NCT00157885 - A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia. N/A